Balanced news tone
News Sentiment
002422 sentiment intelligence
Sichuan Kelun Pharmaceutical Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
74/100 classification confidence.
directly relevant articles
high-authority source matches
+1.9% over one week, +25.0% over four weeks, trend active, and materially above fair value.
Sichuan Kelun Pharmaceutical Receives AAA Rating From China's Lianhe Credit; Shares Slide 10%
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Sichuan Kelun Pharmaceutical Receives AAA Rating From China's Lianhe Credit; Shares Slide 10%
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 17 Jul 2026 05:53
- Source
- Moomoo
Chinese pharmaceutical companies are transitioning from 'product internationalization' to 'industrial globalization,' highlighting investment opportunities in the CXO sector.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 23:42
- Source
- 富途牛牛
Kelun Pharma Cites No New Report to Justify 20% Stock Rally
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:12
- Source
- Moomoo
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Aug 2025 07:00
- Source
- PR Newswire
Merck discontinues some cancer drug development with China's Sichuan Kelun
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Oct 2023 07:00
- Source
- Reuters
Sichuan Kelun-Biotech Opens Books For $208 Million Hong Kong IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2023 07:00
- Source
- CEO Insights Asia
Merck puts eye-popping $9.3B on the line in lopsided ADC deal with Kelun-Biotech
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Dec 2022 08:00
- Source
- Fierce Biotech
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 22 Dec 2022 08:00
- Source
- Business Wire